Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : T/FIF, a New Plateau -- Ignore unavailable to you. Want to Upgrade?

To: scaram(o)uche who wrote (341)	11/16/2000 1:15:23 PM
From: nigel bates	Respond to of 2243

Von Emster is regarded as one of the first money managers to cash in on the genomics revolution. Can't deny that, but I can't help feeling my interpretation is a little different to what's intended. (g) ...three-year cumulative return of 240%. The fund has posted a year-to-date return of 67%, while the Nasdaq Biotechnology Index is up only 32%. Bet those VCap guys are quaking in their boots. nig